No matches
Rhinology

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.
Eugenio De Corso
MD, PhD
Eugenio De Corso

Related resources

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

expert video
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

expert video
IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

expert video
IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

expert video
IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

expert video
ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Loss of Smell in CRSwNP Patients

Podcast
ADVENT On Air | Remission in CRSwNP

ADVENT On Air | Remission in CRSwNP

Podcast
EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

expert video
EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

expert video
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

expert video
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

expert video
Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

expert video
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

expert video
Connecting Type 2 Inflammation to CRSwNP

Connecting Type 2 Inflammation to CRSwNP

expert video
CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

interactivity
IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

expert video
IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

expert video
IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

expert video
IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

expert video
CRSwNP: A Chronic Type 2 Inflammatory Disease

CRSwNP: A Chronic Type 2 Inflammatory Disease

expert video
What proportion of patients can achieve control in CRSwNP?

What proportion of patients can achieve control in CRSwNP?

expert video
Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

expert video
What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

expert video
When is the right time to consider a biologic in patients with CRSwNP?

When is the right time to consider a biologic in patients with CRSwNP?

expert video
How often do you suggest to assess sense of smell?

How often do you suggest to assess sense of smell?

expert video
How does a decrease in smell affect sleep disturbance? Is there any direct relation?

How does a decrease in smell affect sleep disturbance? Is there any direct relation?

expert video
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

expert video
Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

expert video
CRSwNP Triathlon: An Interactive Learning Experience

CRSwNP Triathlon: An Interactive Learning Experience

interactivity
Loss of Smell is a Key Symptom of CRSwNP

Loss of Smell is a Key Symptom of CRSwNP

interactivity
Partnering With Patients: Scores That Matter in CRSwNP

Partnering With Patients: Scores That Matter in CRSwNP

interactivity
2025 ADVENT Forum | Potential for Disease Modification in the Airway

2025 ADVENT Forum | Potential for Disease Modification in the Airway

expert video

Learning objectives

  • Evaluate recently published definitions of remission in CRSwNP with an eye toward improving patient outcomes

Description

Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.

Tags
expert insightsstandard of caredisease controlguidelinesadverse eventsquality of life
MAT-GLB-2401111 - 1.0 - 04/2024

About this expert

Rhinology

Eugenio De Corso

MD, PhD

Adjunct Professor of Otorhinolaryngology | Catholic University of the Sacred Heart, Milan, Italy

See author’s profile
Eugenio De Corso

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: DenmarkChange country/region